BCL2 and cancer: Emerging evidence indicated that transiently activated JNK promotes cancer cell survival by modulating JNK-Bcl-2/Bcl-xL-Bax/Bak- as well as Cyt-C/caspase-3-dependent pathways [19,23,24].